CJC-1295 — Growth hormone releasing hormone (GHRH) analog + Growth hormone secretagogue (GHS)
CJC-1295: GHRH analog that binds GHRH receptor to stimulate pituitary GH release with extended half-life via DAC (Drug Affinity Complex) or albumin binding. Ipamorelin: Selective ghrelin mimetic (GHSR agonist) that stimulates GH release without significant cortisol or prolactin elevation. Combined: synergistic GH pulse amplification.
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Growth hormone releasing hormone (GHRH) analog + Growth hormone secretagogue (GHS)
آلية العمل
CJC-1295: GHRH analog that binds GHRH receptor to stimulate pituitary GH release with extended half-life via DAC (Drug Affinity Complex) or albumin binding. Ipamorelin: Selective ghrelin mimetic (GHSR agonist) that stimulates GH release without significant cortisol or prolactin elevation. Combined: synergistic GH pulse amplification.
الوضع التنظيمي
Not FDA approved; research peptides
مستوى الأدلة
Moderate — Phase 2 trials for CJC-1295; Ipamorelin Phase 2 completed; limited large-scale human data